APA (7th ed.) Citation

Rousel, J., Saghari, M., Pagan, L., Nădăban, A., Gambrah, T., Theelen, B., . . . van Doorn, M. B. A. (2023). Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial. International Journal of Molecular Sciences, 24(18), 14315. https://doi.org/10.3390/ijms241814315

Chicago Style (17th ed.) Citation

Rousel, Jannik, et al. "Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis Versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial." International Journal of Molecular Sciences 24, no. 18 (2023): 14315. https://doi.org/10.3390/ijms241814315.

MLA (9th ed.) Citation

Rousel, Jannik, et al. "Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis Versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial." International Journal of Molecular Sciences, vol. 24, no. 18, 2023, p. 14315, https://doi.org/10.3390/ijms241814315.